Quarterly ResultAug 6, 2026, 04:42 PM
Aclaris Q2 Net Loss $(21.5)M, R&D Up 58%; Raised $57.9M
AI Summary
Aclaris Therapeutics reported a net loss of $(21.5) million for Q2 2026, a 39.4% increase from Q2 2025, with R&D expenses rising 57.8% to $18.1 million. Total revenue for the quarter decreased by 8.3% to $1.6 million. For the six months ended June 30, 2026, the net loss was $(41.3) million, and the company raised $57.9 million net from an at-the-market common stock offering. The company stated it has sufficient liquidity to fund operations for over 12 months.
Key Highlights
- Q2 2026 net loss increased 39.4% to $(21.5) million.
- Q2 2026 total revenue decreased 8.3% to $1.6 million.
- Research and development expenses rose 57.8% to $18.1 million in Q2 2026.
- Net loss for the six months ended June 30, 2026, was $(41.3) million.
- Raised $57.9 million net from an at-the-market common stock offering.
- Cash, cash equivalents, and marketable securities totaled $170.6 million as of June 30, 2026.
- Net cash used in operating activities for six months was $(38.0) million.
Price Impact
More from ACRS